

# FAGRON N.V.

ISIN: BE0003874915

WKN: -

Asset Class: **Stock**

## Company

2024/08/16 10:12:32



Price

**18.96**

EUR

Difference

0.21%(0.04)



## Contact Details

FAGRON NV Tel: +32-8-001-28-80  
-- Fax: +32-9-216-24-91  
Venecoweg 20A Web: <http://www.fagron.com>  
9810 Nazareth E-mail: -

## Company Profile

Fagron NV engages in the development, marketing, and distribution of healthcare products and services. It operates through the following segments: Essentials, Brands, and Compounding Services. The Essential segment focuses on supplying raw materials to community and hospital pharmacies for pharmaceutical compounding. The Brands segment is involved in developing and producing semi-finished products and vehicles, such as emulsions, powder mixtures, creams, and other excipients, as well as total concepts and equipment for pharmaceutical compounding. The Compounding Services segment offers community and hospital pharmacies with ready-to-use non-sterile compounded medicine in those countries where it is permitted. The company was founded in 1990 and is headquartered in Nazareth, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023          |                        | 2022        |                        | 2021        |                        |
|--------------------------------|---------------|------------------------|-------------|------------------------|-------------|------------------------|
|                                | Assets        | Liabilities and equity | Assets      | Liabilities and equity | Assets      | Liabilities and equity |
| Current assets                 | 335,901,000   |                        | 318,010,000 |                        | 233,711,000 |                        |
| Common stock capital           |               | 524,531,000            |             | 521,238,000            |             | 520,785,000            |
| Fixed assets                   | 671,053,000   |                        | 653,000,000 |                        | 566,710,000 |                        |
| Equity capital of a company    |               | 467,626,000            |             | 410,518,000            |             | 325,466,000            |
| Cash and cash equivalents      | 133,008,000   |                        | 125,337,000 |                        | 70,646,000  |                        |
| Accrued liabilities            |               | 4,589,000              |             | 4,761,000              |             | 6,113,000              |
| Other assets                   | -             |                        | -           |                        | -           |                        |
| Current liabilities            |               | 175,258,000            |             | 171,009,000            |             | 145,062,000            |
| Prepayments and accrued income | -             |                        | -           |                        | -           |                        |
| Non-current liabilities        |               | 364,070,000            |             | 389,483,000            |             | 329,893,000            |
| Different income               |               | -                      |             | -                      |             | -                      |
| Other liabilities              |               | 440,000                |             | 0                      |             | 0                      |
| Total assets                   | 1,006,954,000 | 1,006,954,000          | 971,010,000 | 971,010,000            | 800,421,000 | 800,421,000            |

## Balance notes

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS    | IFRS    | IFRS    |
| Employees           | 3,282   | 3,035   | 2,846   |
| Equity ratio        | 46.82%  | 42.89%  | 41.33%  |
| Debt-equity ratio   | 113.56% | 133.14% | 141.95% |

## Others

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 15.87% | 20.17% | 20.10% |

**Income statement**

|  | <b>2023</b> | <b>2022</b> | <b>2021</b> |
|--|-------------|-------------|-------------|
| <b>Turnover</b>  | 762,991,000 | 683,881,000 | 573,808,000 |
| <b>Net income</b>  | 70,547,000  | 69,612,000  | 61,004,000  |
| <b>EBIT</b>  | 102,100,000 | 100,256,000 | 88,099,000  |
| <b>Operating income before taxes</b>                                 | 84,445,000  | 87,769,000  | 76,820,000  |
| <b>Cash Flow</b>   | 107,379,000 | 97,551,000  | 64,650,000  |
| <b>Net interest income</b>   | -17,655,000 | -12,487,000 | -11,279,000 |
| <b>Research and development expenses</b>                             | -           | -           | -           |
| <b>Income taxes</b>  | 13,401,000  | 17,703,000  | 15,442,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | 0           | 0           | 0           |
| <b>Revenues per employee</b>   | 232,477     | 225,331     | 201,619     |

**Board of Directors**

|                        |                               |
|------------------------|-------------------------------|
| Koen Hoffman           | Chairman of Supervisory Board |
| Ann Rita Desender      | Member of Supervisory Board   |
| Els Vandecandelaere    | Member of Supervisory Board   |
| Karin de Jong          | Member of Supervisory Board   |
| Klaus Röhrig           | Member of Supervisory Board   |
| Neeraj Sharma          | Member of Supervisory Board   |
| Robert J. W. ten Hoedt | Member of Supervisory Board   |

**Members of Management Board**

|                |                               |
|----------------|-------------------------------|
| Rafael Padilla | Chairman of Managing Board    |
| Karin de Jong  | Member of Executive Committee |
| Vera Bakker    | Member of Executive Committee |